UK's regulatory and legislative double standards in the treatment of psychedelics and drugs for assisted suicide.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 42464460.
- Also identified by DOI 10.1192/bjp.2026.10731.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This editorial highlights the UK's drug regulatory double standards. Drugs for assisted suicide would bypass standard regulation despite limited evidence, while psychedelics face significant barriers despite promising evidence internationally. I argue that drugs for assisted suicide should meet the same regulatory standards, and psychedelics should be rescheduled to enable further clinical research.